Tags: clinical trial + drug company.with.MS

Sort by: Date / Title / URL

1. PharmaLive: BioMS Medical's Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
   The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS.
   25-07-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, relapsing remitting, rrms by admin
2. Pipex Pharmaceuticals' Oral TRIMESTA Initiates Dosing in Phase II/III Clinical Trial for Multiple Sclerosis
   TRIMESTA (oral estriol), its proprietary therapy for multiple sclerosis (MS), in a multi-center Phase II/III clinical trial for the treatment of women with relapsing-remitting MS.
   17-07-2007 to clinical trial, drug company, drugs, multiple sclerosis, pregnancy, relapsing remitting by admin
3. Rebif - multiple sclerosis encyclopaedia
   Here is a table of clinical trials of Rebif.
   13-07-2007 to clinical trial, drug company, drugs, rebif, relapsing remitting, spms by admin
4. PharmaLive: Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
   The MS-F204 study, which is conducted under a Special Protocol Assessment (SPA) issued by the Food and Drug Administration (FDA), will evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS.
   07-06-2007 to clinical trial, drug company, drugs, fampridine, ms, multiple sclerosis by admin
5. BioMS Medical initiates enrollment in pivotal U.S. phase III multiple sclerosis trial
   the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis
   07-06-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, spms by admin
6. MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial - PipelineReview.com | Business Intelligence Center
   Positive clinical findings from the 12-month core period of a Phase II clinical trial of MN-166 that measures both surrogate (radiological) and clinical outcomes over two years of treatment in 297 patients with relapsing multiple sclerosis (MS).
   01-04-2007 to clinical trial, drug company, drugs, mn-166., multiple sclerosis, relapsing remitting by admin
7. Inside Bay Area - Firm optimistic with MS drug trials
   In the latest trial, daclizumab was given in combination with a standard therapy, interferon-beta, and was effective up to 24 weeks, the companies said in a statement.
   01-04-2007 to clinical trial, daclizumab, drug company, drugs, interferon, multiple sclerosis by admin
8. Artielle ImmunoTherapeutics Initiates Clinical Trials For Multiple Sclerosis
   Artielle ImmunoTherapeutics, Inc. today announced that the company has initiated a Phase I clinical trial to evaluate its novel drug candidate, RTL1000, for the treatment of multiple sclerosis (MS). RTL1000 is a novel protein drug
   01-04-2007 to clinical trial, drug company, drugs, multiple sclerosis, rtl1000 by admin
9. Biogen, PDL drug passes clinical trial
   Patients given daclizumab every two weeks had a significantly reduced lesions at week 24 compared with those in the placebo group.
   13-03-2007 to clinical trial, daclizumab, drug company, drugs, interferon, multiple sclerosis, relapsing remitting, treatment by admin
10. TERMS
    The TERMS (Tovaxin for Early Relapsing Multiple Sclerosis) study is testing Tovaxin, an autologous T-Cell vaccination in patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
    15-02-2007 to clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, tovaxin, treatment by admin
11. Merck Serono Has Initiated The Onward Study To Evaluate Oral Cladribine As Add-On Treatment For Multiple Sclerosis - PipelineReview.com | Business Intelligence Center
    Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
    07-02-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, rebif, research, treatment by admin
12. BioMS Medical Cleared by FDA to Initiate Pivotal Phase III Multiple Sclerosis Trial
    "The clearance to proceed with a phase III trial in the US is asignificant step towards bringing MBP8298 to the worldwide market," saidKevin Giese, President and CEO of BioMS Medical.
    20-01-2007 to canada, clinical trial, drug company, drugs, mbp8298, multiple sclerosis, secondary progressive by admin
13. Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
    Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
    17-01-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, research, rrms, treatment by admin
14. Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
    Serono announced today the initiation of a Phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of Rebif(R) (interferon beta-1a 44 mcg, three times a week or once a week) on the time to
    13-12-2006 to clinical trial, drug company, drugs, multiple sclerosis, rebif, relapsing remitting, research, rrms by admin
15. Roskamp Institute Looking for Volunteers for Multiple Sclerosis Research Study
    The Roskamp Institute announced today its participation in a pharmaceutical sponsored research study for relapsing-remitting Multiple Sclerosis (MS) sufferers.
    08-12-2006 to clinical trial, drug company, drugs, fingolimod, multiple sclerosis, relapsing remitting, research, rrms, study by admin

First / Previous / Next / Last / Page 1 of 2